论文部分内容阅读
目的:比较头孢哌酮-舒巴坦与头孢他啶对脑卒中患者伴肺部感染的临床疗效。方法:选取2015年7月—2016年10月期间收治的脑卒中伴肺部感染患者58例临床资料,采用抽签方式将其分为对照组与治疗组(每组29例);对照组患者给予头孢他啶静脉滴注治疗,治疗组患者则给予头孢哌酮-舒巴坦静脉滴注治疗,比较两组患者治疗1周后的病原菌清除率和总有效率。结果:治疗后治疗组患者病原菌清除率为89.66%高于对照组为65.52%(P<0.05),治疗后的总有效率为96.55%高于对照组为79.31%(P<0.05)。结论:头孢哌酮-舒巴坦对脑卒中患者伴肺部感染的临床疗效优于头孢他啶,能有效清除患者体内病原菌。
Objective: To compare the clinical efficacy of cefoperazone-sulbactam and ceftazidime against stroke patients with pulmonary infection. Methods: Fifty-eight patients with stroke and pulmonary infection admitted from July 2015 to October 2016 were selected and randomly divided into control group and treatment group (n = 29 in each group) by lottery. Patients in control group Ceftazidime intravenous infusion, the treatment group was given cefoperazone - sulbactam intravenous infusion of two groups of patients after treatment compared to the pathogen clearance rate and total effective rate. Results: After the treatment, the clearance rate of pathogenic bacteria in the treatment group was 89.66% higher than that in the control group (65.52%, P <0.05). The total effective rate after treatment was 96.55% higher than that in the control group (79.31%, P <0.05). Conclusion: Cefoperazone - sulbactam is superior to ceftazidime in stroke patients with pulmonary infection, which can effectively remove pathogens in patients.